文献速递腹部泌尿生殖CT

基于CT的体成分与转移性肾癌免疫治疗生存的关联:多中心回顾性研究

Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study.
PubMed 文献 · Eur Radiol · 2022-12-20

该多中心回顾性研究纳入251例接受抗PD1治疗的转移性肾细胞癌患者,分析CT评估的体成分与生存结局的关系。结果显示皮下脂肪百分比(SAT%)独立预测无进展生存和总生存,高SAT%患者肿瘤内PD1+CD8+T细胞密度和比例更高。

要点

  • SAT%是mRCC免疫治疗预后的独立预测因子,高SAT%提示更好生存。
  • 肥胖(BMI分类)及骨骼肌面积、内脏脂肪等未显示与生存显著相关。
  • 高SAT%患者肿瘤内PD1+CD8+T细胞密度和比例更高,可能解释更好应答。

诊断标准与关键数值

  • SAT%作为连续变量独立预测PFS(HR 0.02,95%CI 0.01-0.11)和OS(HR 0.05,95%CI 0.01-0.39)。
  • 多因素模型中SAT%作为连续变量调整后HR for PFS 0.01(95%CI 0.00-0.04),HR for OS 0.08(95%CI 0.01-0.72)。
  • 肥胖患者PFS(HR 0.61,95%CI 0.27-1.42)和OS(HR 1.09,95%CI 0.38-3.13)无显著改善。
  • SM、VAT、SAT与生存结局无关(所有p>0.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the association of computed tomography-assessed body composition with survival outcomes of metastatic renal cell carcinoma (mRCC) received immunotherapy.

METHODS: In this multicenter, retrospective study, we reviewed 251 mRCC patients who received anti-PD1 from five centers. We analyzed the relationship between BMI, skeletal muscle area (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and subcutaneous adipose percentage (SAT%) with progression-free survival (PFS) and overall survival (OS). The spatial localization T cells was investigated by multiplex immunofluorescence.

RESULTS: Among 224 evaluable patients, 23 (10.3%) patients were underweight, 118 (52.7%) had normal weight, 65 (29%) were overweight, and 18 patients (8%) were obese. The median age was 55 years and most patients were male (71%). No significant improvement in PFS (HR, 0.61; 95% CI, 0.27-1.42) or OS (HR, 1.09; 95% CI, 0.38-3.13) was observed for the obese patients. Besides, SM, VAT, and SAT were not associated with survival outcomes (all p > 0.05). Interestingly, SAT% independently predicted PFS (as continuous variable, HR: 0.02; 95% CI, 0.01-0.11) and OS (HR:0.05; 95% CI, 0.01-0.39), which remained significant in multivariate modeling (as continuous variable, adjusted HR for PFS, 0.01; 95% CI, 0.00-0.04; adjusted HR for OS, 0.08; 95% CI, 0.01-0.72). These associations were consistent in subgroup analysis of different gender, BMI, PD-L1 positive, and sarcopenia group. Tumor of high SAT% patients had a higher intratumoral PD1+ CD8+ T cell density and ratio.

CONCLUSION: High SAT% predicts better outcomes in mRCC patients treated with anti-PD1 and T cell location may account for the better response.

KEY POINTS: • CT-based subcutaneous adipose percentage independently predicted progression-free survival and overall survival. • Patients with a higher subcutaneous adipose percentage had a higher intratumoral PD1+ CD8+ T cell density and ratio.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Dong, Qu, et al. Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study. Eur Radiol. 2022. PMID: 36538073. doi:10.1007/s00330-022-09345-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。